Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

839.96 +105.06 (+14.30%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
7 Explosive Growth Stocks Set to Soar in 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga
3 Top-Performing Stocks Beating the Big Names in 2024
The following top-performing stocks may continue to gain as the Magnificent Seven runs out of steam in July. 
Via InvestorPlace
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Viking Therapeutics Inc (NASDAQ:VKTX) shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials. 
Via Benzinga
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company stock is trading lower on Thursday after Viking Therapeutics announced the advancement of its novel treatment for obesity, VK2735. 
Via Benzinga
3 Companies Gearing Up for a Stock Split
These stock split candidates could follow the route of Nvidia, Walmart and Chipotle Mexican Green in the near future. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug. 
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Investors have strong opinions on Tesla but not on LVMH or Eli Lilly, Musk agrees on Twitter. Tesla's controversial CEO and recent financial struggles may explain heightened interest. 
Via Benzinga
3 Fabulous Growth Stocks to Buy and Hold Forever
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Their yields may seem low, but these stocks have been growing their dividend payments at a fast pace. 
Via The Motley Fool
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Could today's momentum continue? 
Via The Motley Fool
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
These stocks to buy before earnings are likely to jump higher after the companies behind them report their Q2 financial results. 
Via InvestorPlace
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All. 
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term. 
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
SPDR ETF Report For Friday, July 19
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 19. 
Via Talk Markets
Topics ETFs
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Skyrocketing demand for GLP-1 medications for weight loss is causing shortages, impacting type 2 diabetics. While some insurers are limiting off-label use, government agencies have yet to prioritize... 
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.